Sage Journals: Discover world-class research

Abstract

As a result of recent therapeutic trials, recombinant Interferon beta (r/FNβ)-1b and-1a as well as Copolymer 1 (COP 1) and to some extent unspecific immunosuppressants have been accepted as partially efficient treatments of relapsing-remitting MS. In view of partially effective single treatments, the question arises if combination of two or even more agents could improve efficacy without increasing side effects. The theoretical background of possible combinations is discussed. The selection of combination partners should be based on their proven efficacy as Singh treatment, on their mode of action and their distinct target in the pathogenetic cascade of events and on their specific side effect prof ile. Combination regimens selected in this way should undergo evaluation in short term early phase II studies and if the results are positive enter phase III studies. The use of surrogate markers (especially MRI-findings) may help to accelerate this process. Combinations that could enter phase II and III studies in the near future are r/FNβ with unspecific immunosuppressants, e.g. Azathioprine or Methotrexate and r/FNβ with COP I. Combinations including agents just entering phase I and II studies as a single treatment may be more promising for the future.

Keywords

multiple sclerosis treatment drug combinations review Interferon β Azathioprine

Get full access to this article

View all access options for this article.

References

1 Hughes R . (1994) Editorial: Immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry 57: 3–6.

2 Ebers GC . (1994) Treatment of multiple sclerosis. Lancet 343: 275–279.

3 Polman CH , Hartung H-P . (1995) The treatment of multiple sclerosis: current and future. Curr Opin Neurol 8: 200–209.

4 Kappos L . (1995) Multiple Sklerose: diagnostisches Vorgehen und neue therapeutische Entwicklungen. Schweiz Med Wochenschr 125: 1251–1263.

5 Beck RW et al. (1992) A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. New Engl J Med 326: 581–588.

6 Beck RW et al. (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329: 1764–1769.

7 IFNB Multiple Sclerosis Study Group . (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661.

8 Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39: 285–294.

9 Johnson KP et al. (1995) Coplymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268–1276.

10.

10 Yudkin PL et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338: 1051–1055.

11.

11 Goodkin DE et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 37: 30–40.

12.

12 Whitaker JN , Mitchell GW . (1993) Experimental allergic encephalomyelitis as a guide to the understanding and treatment of multiple sclerosis. Ann Neurol 34: 636–637.

13.

13 Wekerle H et al. (1994) Animal Models. Ann Neurol 36: S47–S53.

14.

14 Salk J et al. (1980) Myelin basic protein studies in experimental allergic encephalomyelitis and multiple sclerosis. In: Davidson AN , Cuzner MC (eds). The suppression of experimental allergic enceohalomyelitis and mutliple sclerosis, Academic Press: London.

15.

15 Dijkstra CD , Polman CH , Berkenbosch F . (1993) Multiple Sclerosis: some possible therapeutic opportunities. TiPS 14: 124–129.

16.

16 Whitaker JN , McFarland HF , Rudge P , Reingold SC . (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1: 37–47.

17.

17 Miller DH et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted action guidelines (CEC) guidelines. J Neurol Neurosurg Psychiatry 54: 683–688.

18.

18 Miller DH et al. (1996) Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 39: 6–16.

19.

19 Kappos L , Radue EW . (1991) Magnetische Resonanztomographie bei Multipler Sklerose: Eine Bestandsaufnahme. Klin Neuroradiol 2: 83–140.

20.

20 McDonald WI . (1993) The dynamics of multiple sclerosis. J Neurol 240: 28–36.

21.

21 Ellison GW et al. (1989) A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 39: 1018–1026.

22.

22 Kappos L et al. (1988) Cyclosporine vs azathioprine in the long-term treatment of MS-results of the German multicenter study. Ann Neurol 23: 56–63.

23.

23 Rudge P et al. (1989) Randomised double blind controlled trial of cyclosporin in multiple sclerosis (published erratum appears in J Neurol Neurosurg Psychiatry 1989 Jul; 52(7): 932). J Neurol Neurosurg Psychiatry 52: 559–565.

24.

24 The Multiple Sclerosis Study Group . (1990) Efficacy and toxicity of Cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Ann Neurol 27: 591–605.

25.

25 Gold R et al. (1990) Combined immunosuppression with Azathioprine and Cyclosporine: results of an open, MRI controlled pilot study. J Neurol 237 (Suppl 1): 20.

26.

26 Gold R et al. (1991) Erfahrungen einer offenen, NMR kontrollierten Pilotstudie mit kombinierter Immunosuppression bei MS. Verh Dtsch Ges Neurol 6: 212–213.

27.

27 Wekerle H , Linington C , Lassmann H , Meyermann R . (1986) Cellular immune reactivity within the CNS. Trends Neurosci 9: 271–277.

28.

28 Hohlfeld R et al. (1995) The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology 45 (suppl 6): S33–S38.

29.

29 Hartung H-P . (1995) Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol 8: 191–199.

30.

30 Panitch H . (1995) Neuroimmunol Suppl 1: 15 (Abstract).

31.

31 The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis. Neurology 45: 1277–1285.

32.

32 Arnason BGW , Jensen M , Lledo A , Dayal A . (1995) Neurology 45 (Suppl 4): A437 (Abstract).

33.

33 Edan G et al. (1995) J Neurol 242 (Suppl 2): S38 (Abstract).

34.

34 Sipe JC et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344: 9–13.

Combinations of drugs

Abstract

Keywords

Get full access to this article

References